Himalaya Therapeutics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

A clinical-stage biotech developing novel antibody therapies for oncology and immunology.

OncologyImmunology

Advanced antibody engineering platform for developing monoclonal and bispecific antibodies with optimized binding and functional properties.

Large and growing demand for novel immuno-oncology treatments in China and globally.

Clinical trial failures or inability to differentiate from established checkpoint inhibitors could hinder progress.

Faces intense competition from global oncology leaders and a crowded field of Chinese biotechs developing similar antibody therapies.